We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+1.98%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$489M
AUM Growth
+$31.8M
Cap. Flow
+$66.3M
Cap. Flow %
13.55%
Top 10 Hldgs %
49.33%
Holding
85
New
24
Increased
27
Reduced
16
Closed
16

Top Buys

Rank Stock Value
1
ETNB
89bio
ETNB
+$12.4M
2
KALV
KalVista Pharmaceuticals
KALV
+$11.1M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$9.19M
4
SLNO
Soleno Therapeutics
SLNO
+$8.1M
5
ORIC icon
Oric Pharmaceuticals
ORIC
+$7.71M

Top Sells

Rank Stock Value
1
PLRX icon
Pliant Therapeutics
PLRX
+$17.3M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$15M
3
PSTX
Poseida Therapeutics, Inc. Common Stock
PSTX
+$9.72M
4
SRRK icon
Scholar Rock
SRRK
+$7.92M
5
COGT icon
Cogent Biosciences
COGT
+$7.18M

Sector Composition

Rank Sector Weight
1 Healthcare 97.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KNSA icon
51
Kiniksa Pharmaceuticals
KNSA
$5.8B
$1.96M 0.4%
+88,215
New +$1.82M
SLDB icon
52
Solid Biosciences
SLDB
$794M
$1.67M 0.34%
+452,239
New +$1.94M
CMPX icon
53
Compass Therapeutics
CMPX
$344M
$1.66M 0.34%
+874,869
New +$2.33M
CCCC icon
54
C4 Therapeutics
CCCC
$385M
$1.41M 0.29%
882,300
-338,831
-28% -$1.01M
KALA icon
55
KALA BIO
KALA
$14.1M
$1.41M 0.29%
4,922
+301
+7% +$114K
UNCY icon
56
Unicycive Therapeutics
UNCY
$137M
$1.39M 0.28%
241,349
-7,322
-3% -$44.7K
ABVX
57
Abivax
ABVX
$10.8B
$1.32M 0.27%
210,901
-74,219
-26% -$502K
KOD icon
58
Kodiak Sciences
KOD
$2.6B
$1.24M 0.25%
441,807
-558,193
-56% -$3.04M
SION
59
Sionna Therapeutics
SION
$2.13B
$1.19M 0.24%
+114,138
New +$1.86M
IFRX icon
60
InflaRx
IFRX
$250M
$1.18M 0.24%
+1,161,567
New +$2.19M
MRSN
61
DELISTED
Mersana Therapeutics
MRSN
$1.06M 0.22%
+123,540
New +$1.91M
MODD icon
62
Modular Medical
MODD
$12.9M
$1.05M 0.21%
31,963
-10,438
-25% -$348K
RADX
63
Radiopharm Theranostics
RADX
$25.2M
$901K 0.18%
187,406
– –
AARD
64
Aardvark Therapeutics
AARD
$144M
$897K 0.18%
+119,496
New +$1.34M
XENE icon
65
Xenon Pharmaceuticals
XENE
$6.06B
$340K 0.07%
+10,121
New +$384K
AVDL
66
DELISTED
Avadel Pharmaceuticals
AVDL
$308K 0.06%
+39,366
New +$330K
GUTS icon
67
Fractyl Health
GUTS
$109M
$283K 0.06%
237,448
+60,526
+34% +$96.6K
VXRT
68
DELISTED
Vaxart
VXRT
$278K 0.06%
683,825
-393,957
-37% -$253K
RCKTW icon
69
Rocket Pharmaceuticals Warrant
RCKTW
$149K
$4.93K ﹤0.01%
104,828
– –
COGT icon
70
Cogent Biosciences
COGT
$6.65B
– –
-921,137
Closed -$7.18M
EYPT icon
71
EyePoint Inc
EYPT
$1.03B
– –
-121,274
Closed -$903K
GERN icon
72
Geron
GERN
$828M
– –
-920,022
Closed -$3.26M
INCY icon
73
Incyte
INCY
$24.2B
– –
-49,000
Closed -$3.38M
KPTI icon
74
Karyopharm Therapeutics
KPTI
$43.5M
– –
-39,733
Closed -$403K
NMRA icon
75
CALL
Neumora Therapeutics
NMRA
$298M
– –
-147,200
Closed -$1.56M
1 2
3
4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return

Silverarc Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Silverarc Capital Management held 85 positions worth $489M, up 7% from $457M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Silverarc Capital Management deployed $66.3M of net new capital in Q1 2025, opening 24 new positions and adding to 27 existing holdings. Its largest new stake was Neurocrine Biosciences: 72,583 shares worth $8.03M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier.

On the sell side, the largest reduction was Centessa Pharmaceuticals, an estimated $5.99M trimmed.

  • Silverarc Capital Management's largest Q1 2025 buy was Neurocrine Biosciences: 72,583 shares worth $8.03M.
  • Silverarc Capital Management added most to 89bio in Q1 2025, an estimated $12.4M increase.
  • Silverarc Capital Management's biggest Q1 2025 reduction was Centessa Pharmaceuticals, cutting an estimated $5.99M.
  • Silverarc Capital Management fully exited Pliant Therapeutics in Q1 2025, selling an estimated $17.3M.
  • Silverarc Capital Management's ten largest holdings make up 49% of its $489M portfolio in Q1 2025.
  • Silverarc Capital Management opened 24 new positions and closed 16 in Q1 2025.
  • Silverarc Capital Management's portfolio value rose 7% quarter-over-quarter to $489M.

Based on Silverarc Capital Management's 13F filing for Q1 2025, filed 14 May 2025.